The complex synthesis process of drug-linker manufacturing and conjugation stages opens the door for ADC impurities that are difficult to identify and control and demonstrate confidence to regulatory bodies

Join this workshop led by big pharma leaders and members of the IQ consortium to investigate the playbook for ADC impurity process and control strategy.